IDRX 73
Alternative Names: IDRX-73Latest Information Update: 18 Mar 2024
At a glance
- Originator Blueprint Medicines
- Developer IDRx
- Class Antineoplastics; Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal stromal tumours